ArticleTranslational lung cancer research2025
Induction chemoimmunotherapy and surgery for unresectable stage III non-small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Feasibility of neoadjuvant immunochemotherapy in potentially resectable non-small cell lung cancer: a single-arm meta-analysis.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Concurrent chemoradiation plus consolidation immunotherapy is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC), however, whether induction chemoimmunotherapy plus surgery can provide good efficiency and safety for this population is unclear. This study aims to evaluate the efficacy and safety of induction chemoimmunotherapy plus surgery in unresectable stage III NSCLC. Methods: Patients with stage I-III NSCLC receiving neoadjuvant/induction chemoimmunotherapy were screened. Kaplan-Meier method, propensity score matching (PSM), Cox regression, and subgroup and sensitivity analysis were used for comparation in disease-free survival (DFS) and overall survival (OS). Perioperative safety was also analyzed. Results: A total of 425 NSCLC patients underwent neoadjuvant/induction chemoimmunotherapy plus surgery consisting of 278 with unresectable stage III and 147 with resectable IB-IIIA disease were enrolled. DFS was comparable between unresectable and resectable cohort before [hazard ratio (HR): 0.95, 95% confidence interval (CI): 0.65-1.38, P=0.77] and after (HR: 1.08, 95% CI: 0.66-1.76, P=0.75) PSM. In addition, OS before (HR: 1.07, 95% CI: 0.57-2.02, P=0.83) and after (HR: 1.40, 95% CI: 0.63-3.09, P=0.41) PSM had no significant difference between the two cohorts. The 3-year DFS (68.7% Conclusions: Induction chemoimmunotherapy plus surgery can bring satisfying DFS/OS with good safety for unresectable stage III NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.